BDKRB1 and arthritic joint disease: Cd13–/– mice treated with a B1R antagonist exhibited a reduction in arthritis development compared with WT mice, but a significant decrease in arthritis did not appear until day 8, suggesting the importance of both ligands of B1R in arthritis development in this model, bradykinin early and sCD13 later.